FDA Will Wait for Trial Results on Vytorin

Early findings saw no medical benefit; heart expert calls it 'second-line' medication

By Steven Reinberg
HealthDay Reporter

Related Encyclopedia • Abdominoplasty • Acidophilus • Alzheimer's Disease • Aneurysms More... Related Healthscout Videos The On-X Valve PROACT Trial The On-X Heart Valve: Longevity With Less Reliance on Coumadin Tissue Valves vs. Mechanical Valves What is the difference between heart valve repair and replacement? More... Related Animations • Alzheimer's Disease Video Animation • Angioplasty • Coronary Bypass Surgery • Erectile Dysfunction More... Related Drug Information • Accupril • Actonel • Altace • Avapro More... Related News Articles • FDA Warns Consumers Not to Eat Peanut Butter Products • Cholesterol Levels May Not Measure Cardiac Risk • Sepsis Therapy in Preemies Fails to Boost Survival • FDA Warns of Skin-Numbing Drug Dangers More...

FRIDAY, Jan. 25 (HealthDay News) -- The controversy surrounding the highly promoted cholesterol-lowering drug Vytorin continued Friday when U.S. health officials said they would review the medication's effectiveness, but only after final trial results were completed.

The debate began earlier this month when preliminary results of the so-called Enhance trial showed that Vytorin -- a combination of two cholesterol drugs -- had little medical benefit.

Text Continues Below

---

"We have not yet received a final study report and can't explain why Vytorin didn't lead to lesser amounts of plaque compared to patients treated with simvastatin alone," Dr. John Jenkins, director of the FDA's Office of New Drugs, Center for Drug Evaluation and Research, said during an afternoon teleconference.

A study released Jan. 14 by the makers of Vytorin found that the drug -- a combination of the Zocor (simvastatin) and Zetia (ezetimibe) -- may be no more effective at reducing the build-up of plaque in the arteries than Zocor alone. About 60 percent of U.S. patients who are taking Zetia now receive the drug as part of Vytorin.

The FDA expects to receive the final report on Vytorin in the next several months, Jenkins said.

"Once we receive the final study report, we estimate it will take as long as six months for us to fully evaluate the results of the Enhance study," he said. "And we will be considering whether any further action is warranted in regard to Zetia or Vytorin, and also whether this study has any impact on our approach to the approval of lipid-lowering drugs."

The Enhance trial found that although cholesterol was lowered, the pace at which artery-clogging plaques formed within vessels almost doubled in patients taking Vytorin, compared to those taking Zocor alone.

The FDA noted the trial was not designed to detect any difference in risk of heart attack or stroke between the two treatments.

Page:  1 | 2 | Next >>